Refine by
Clearside Intravitreal Equipment & Supplies
5 equipment items found
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
Suprachoroidal delivery of an integrin inhibitor suspension could provide targeting, compartmentalization and durability advantages over topical or intravitreal delivery, similar to what we have observed in other preclinical studies of small molecule suspensions, such as triamcinolone acetonide and ...
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
The procedure for suprachoroidal injection is conducted in an office setting and is similar in terms of patient preparation and duration to the procedure for intravitreal injection. Therefore, we believe our products could be incorporated into retina specialists’ standard medical practice. We believe suprachoroidal administration may further enhance the value proposition ...
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
Clearside’s proprietary SCS injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform is inherently flexible and intended to work with established medications, new formulations of medicines, as well as future innovations, that can be delivered via suprachoroidal ...
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
The suprachoroidal space is a potential space that traverses the circumference of the eye’s posterior region and lies internal to the sclera and external to the choroid. The innermost layer of the choroid, known as Bruch’s membrane, is compact. The outermost border is more a zone of transition, consisting of several lamellae with variable thickness. Because of its proximity to the ...
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal use. Axitinib is a tyrosine kinase inhibitor (TKI) currently approved to treat renal cell cancer that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. We believe this broad VEGF blockade may have efficacy advantages over existing retinal ...